title: Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes.
abstract: The global community has committed itself to eliminating new pediatric HIV infections by 2015 and improving maternal, newborn, and child health and survival in the context of HIV. Such objectives require regimens to prevent mother-to-child transmission (pMTCT) which, while being highly efficacious, protect the efficacy of future first-line antiretroviral therapy (ART). Major obstacles to eliminating vertical transmissions globally include low rates of adherence to ART and non-completion of the 'pMTCT cascade' due to programmatic and structural challenges faced by healthcare systems in low-income countries. Providing all pregnant women with lifelong ART regardless of CD4 count/disease stage (Option B+) could be the most effective option to prevent both HIV transmission and resistance, assuming adherence is successfully maintained. This strategy is more likely to achieve sustained undetectable HIV viremia, does not involve ART interruptions, is simpler to implement, and is cost-effective. Where Option B+ is not available, options A (short course zidovudine with single-dose nevirapine and an ARV "tail") and B (combination ART during pregnancy and breastfeeding, with ART cessation after weaning in women not qualifying for ART for their own health) are also efficacious, highly cost-effective and associated with infrequent resistance selection if taken properly.
authors.affiliation: IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. rparedes@irsicaixa.es
authors.forename: Roger
authors.initials: R
authors.lastname: Paredes
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Marconi
authors.forename: Shahin
authors.initials: S
authors.lastname: Lockman
authors.forename: Elaine J
authors.initials: EJ
authors.lastname: Abrams
authors.forename: Louise
authors.initials: L
authors.lastname: Kuhn
mesh_terms: D000349:Africa / Q000453:epidemiology; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D002648:Child; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission* / Q000821:virology; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D010349:Patient Compliance; D011203:Poverty; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents
keywords: HIV; antiretroviral therapy; mother-to-child transmission; prophylaxis; resistance